Skip to Content

Vaxchora Approval History

  • FDA approved: Yes (First approved June 10th, 2016)
  • Brand name: Vaxchora
  • Generic name: cholera vaccine, live, oral
  • Dosage form: Suspension for Oral Administration
  • Company: PaxVax Inc.
  • Treatment for: Cholera Prophylaxis

Vaxchora (cholera vaccine, live, oral) is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1 in adults traveling to cholera-affected areas.

The efficacy of Vaxchora was demonstrated in a randomized, placebo-controlled human cholera challenge study of 197 adults. Vaxchora was shown to be effective in 90.3 percent of those challenged 10 days after vaccination, and 79.5 percent among those challenged three months after vaccination.

Vaxchora is administered orally as a single dose of approximately 100 mL at least 10 days before potential exposure to cholera. Travelers should also follow CDC recommendations for cholera-prevention including safe food and water practices, and frequent hand washing. Common side effects include tiredness, headache, abdominal pain, nausea/vomiting, lack of appetite, and diarrhea.

Development History and FDA Approval Process for Vaxchora

Jun 11, 2016Approval FDA Approves Vaxchora (Cholera Vaccine, Live, Oral) to Prevent Cholera in Travelers

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.